Several studies have been published on the ability of serum or plasma YKL-40 to detect and assess therapeutic responses or as a prognostic predictor of ovarian cancer [9–15], although other studies have not supported this role [28, 29]. This evidence concerns the gene CHI3L1 and ovarian carcinoma.